- Home
- JLS vs ADAG Comparison
JLS vs ADAG Comparison
Compare JLS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | ADAG |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JLS | ADAG |
|---|---|---|
| Price | $18.56 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 26.6K | ★ 103.4K |
| Earning Date | 01-01-0001 | 08-12-2025 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $7,411.34 |
| Revenue Next Year | N/A | $28.29 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.48 | $1.30 |
| 52 Week High | $17.97 | $3.16 |
Technical Indicators
Market Signals| Indicator | JLS | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 56.75 |
| Support Level | $18.48 | $1.78 |
| Resistance Level | $18.75 | $1.99 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 27.28 | 80.00 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.